Get notified when CBIO files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • All Revenue to Date Comes From a Single License Agreement With Kelun For Cr-001 (new) — The company is entirely dependent on one partner for revenue, with no product sales expected in the foreseeable future.
  • We Do Not Currently Solely Own Any Issued Patents or Pending Patent Applications (new) — The company relies on in-licensed patents from Paragon and Kelun, creating a risk of losing rights to its core assets if licenses are terminated.
  • In September 2024, We Issued and Sold 20,000,000 Shares of Series Seed Preferred Stock to Fairmount, Through an Affiliate Fund, At a Purchase Price of $0.20 Per Share, For Total Gross Proceeds of $4.0 Million, Which Qualified As a Related Party Transaction. (new) — A related-party financing at $0.20 per share may not reflect arm's-length terms and raises governance concerns.
NASDAQ: CBIO CRESCENT BIOPHARMA, INC. 424B3

Crescent Biopharma files 424B3 prospectus; net proceeds up to $171.9M, no product revenue, $48.1M net loss

Filed July 30, 2026 · ~1 min read

Key Changes

  • high

    The offering is a resale of shares by selling stockholders; the company receives no proceeds from those sales.

    The Offering view on EDGAR →
  • high

    GAAP net loss for the six months ended June 30, 2026 was $48.1 million, up from $36.9 million a year earlier.

    Risk Factors verify on EDGAR →
  • high

    All revenue to date comes from a single license agreement with Kelun for CR-001; no product sales.

    Risk Factors verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MRSH 10-Q) is open in full — no account needed.

Partner

Trade CBIO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify